Analysis of L-dopa
Van der Pol, H.J.
Pharmaceutisch Weekblad 106(5): 33-36
1971
ISSN/ISBN: 0031-6911 PMID: 5541819 Document Number: 41162
Document emailed within 1 workday
Related Documents
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10Hansson, C.; Rorsman, H.; Rosengren, E. 1981: Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid Acta Dermato-Venereologica 61(2): 147-148
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Zabel, M. 1979: Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA Acta Medica Polona 20(1): 53-54
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Roliński, Z. 1974: Analysis of the aggressiveness-stereotypy complex induced in mice by amphetamine or D,L-dopa. Ii Polish Journal of Pharmacology and Pharmacy 26(3): 369-378
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Dingle, C.J. 1971: The prescribing of L-dopa Medical Journal of Australia 1(19): 1034
Flatberg, P. 1970: 1-dopa for parkinsonism Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 90(10): 1102-1103
Frazer, A.; Mendels, J. 1977: Use of L-DOPA in depression Advances in Biochemical Psychopharmacology 16: 671-675
Andrews, C.J. 1972: Amantadine and L-dopa Australian and New Zealand Journal of Medicine 2(3): 292-293